Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety

BACKGROUND: Osteomyelitis is a challenging infection that can involve 4–6 weeks of intravenous (IV) antibiotics. Dalbavancin, approved for acute bacterial skin and skin structure infections, has potent activity against gram-positive pathogens. This study assessed the efficacy and safety of dalbavanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rappo, Urania, Puttagunta, Sailaja, Shevchenko, Vadym, Shevchenko, Alena, Jandourek, Alena, Gonzalez, Pedro L, Suen, Amy, Mas Casullo, Veronica, Melnick, David, Miceli, Rosa, Kovacevic, Milan, De Bock, Gertjan, Dunne, Michael W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326511/
https://www.ncbi.nlm.nih.gov/pubmed/30648126
http://dx.doi.org/10.1093/ofid/ofy331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326511/
https://www.ncbi.nlm.nih.gov/pubmed/30648126
http://dx.doi.org/10.1093/ofid/ofy331

Ejemplares similares